SCHEMBL2021575

SCHEMBL2021575

NC(=O)c1cc(C(C(N)=O)C2CCOCC2)c2[nH]c3c(c2c1)CCCC3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALOX15 P16050 2/20 0.43
MAPK1 P28482 2/20 0.43
TP53 P04637 2/20 0.43
IKBKB O14920 1/20 0.43
USP2 O75604 1/20 0.43
MAPK10 P53779 1/20 0.43
CASP1 P29466 3/20 0.40
CASP7 P55210 2/20 0.40
HTR1B P28222 2/20 0.39
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
F2 P00734 1/20 0.37
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094478 0.94 MAPT (0.42) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2021582 0.73 SMN1; SMN2 (0.45) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4094487 0.72 SMN1; SMN2 (0.41) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2020896 0.70 HTR1B (0.44) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6447738 0.65 F2 (0.74) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL29643283 0.65 F2 (0.74) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL2050067 0.64 MAPT (0.48) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2050062 0.64 MAPT (0.47) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2048396 0.64 MAPT (0.47) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2048393 0.64 MAPT (0.46) MAPTALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160180-A1 Cannabinoid Receptor Ligands CNR1, CNR2, OPRL1 MAPT 3104/4885ALDH1A1 2240/4885HSD17B10 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.